الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
The impairment of the sense of smell, known as olfactory dysfunction, is a common condition that impacts around 20% of the overall population. The condition has significant consequences for an individual’s well-being, leading to a lower standard of life and heightened rates of illness and death.
Sinonasal disorders, post-viral neurological disorders that produce olfactory dysfunction, and post-traumatic olfactory nerve injuries are the most common causes of olfactory dysfunction..
The incidence of Olfactory Dysfunction has significantly risen, ranging from 30% to 86% among patients, after the emergence of the COVID-19 pandemic in 2019..
The Olfactory Dysfunction can manifest as anosmia, hyposmia, phantosmia, or parosmia, depending on the stage of the disease.
The angiotensin-converting enzyme 2 receptor, which is essential for the entry of SARS-CoV-2, is present in high quantities in nasal epithelial cells. This characteristic puts coronaviruses, among other dangerous microorganisms, capable of inducing post-infectious olfactory dysfunction..
Disruption of cells within the olfactory neuroepithelium can lead to inflammatory alterations within the same neuroepithelium, which in turn can have an impact on the function of olfactory receptor neurons. In addition, such inflammatory changes may exacerbate damage to olfactory receptor neurons and limit subsequent neurogenesis.
The olfactory neuroepithelium and olfactory filae, which are peripheral nerve fibers that pass through the cribriform plate into the nasal cavity, exhibit regenerative capabilities. This characteristic makes them potentially suitable for therapeutic interventions in individuals experiencing olfactory dysfunction..
Platelet-rich Plasma (PRP) refers to an autologous biologic substance obtained from fresh whole blood, characterized by a markedly elevated concentration of platelets.
The anti-inflammatory and pro-regenerative properties of platelet-rich plasma (PRP), which involve the activation of growth factors like transforming growth factor, vascular endothelial growth factor, epidermal growth factor, and insulin-like growth factor, are well known.
It has been applied in various medical situations as a secure therapy that is effective in treating peripheral neuropathies, wound healing, and inflammation.
Specifically, PRP has the capacity to speed up the process of neuroregeneration and axon regeneration, according to earlier studies.
The current study aimed to evaluate of effect of platelet-rich plasma alone & effect of platelet-rich plasma with Dexamethasone in treatment of Post COVID-19 olfactory dysfunction.
The study recruited 50 patients with Post COVID-19 olfactory Dysfunction (Anosmia / hyposmia / Cacosmia) from E.N.T outpatient clinic of Minya university hospital. We divided these patients into two groups: group (A) patients of this group received platelet-rich plasma only in form of injection in olfactory cleft. group (B) patients of this group received platelet-rich plasma and Dexamethasone in form of injection in olfactory cleft.